ArticleBMC medicine2018
Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study.
Article in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Pooled it
- Factors associated with the prescribing of high-dose opioids in primary care: a systematic review and meta-analysis.BMC medicine · 2020Pooled it
- Deep Transcranial Magnetic Stimulation in Patients With Opioid Use Disorder: A Double-Blind, Placebo-Controlled Randomized Trial.Addiction biology · 2025Trial
- Association of Opioid Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events.JAMA network open · 2021Trial
- Differential healthcare costs in individuals with type 2 diabetes and incident chronic kidney disease in Hong Kong: a latent class trajectory analysis.Diabetologia · 2026Article
- Analyzing the Chemical Space of Opioid Receptor Agonists and Antagonists: Insights from Computational Models.ACS omega · 2026Article
- Structural Determinants of μ-Opioid Receptor Antagonism and Respiratory Liability in Phenylfentanyl Analogues.ACS chemical neuroscience · 2026Article
- Heroin addiction modulates transcription factor binding in regulatory regions of the human putamen.Scientific reports · 2026Article
- Out-of-Pocket Healthcare Expenditures Associated with Prescription Opioid Use in Older Adults with Non-cancer Chronic Pain.Drugs & aging · 2026Article
- The Risk Factors and Mortality Among Patients With Different Combination Patterns of Opioids and Benzodiazepines: A Retrospective Study.Pharmacology research & perspectives · 2026Article
- Building epigenetic risk scores of opioid use disorder: Insights from human postmortem brain data.Translational psychiatry · 2026Article
- Postoperative Opioid Receipt After Parotidectomy and Associations With Persistent Opioid Use Disorder.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025Article
- Association Between Different Patterns of Opioid and Benzodiazepine Use and Risks of Emergency Department Visits and Hospitalizations: A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2025Article
- Healthcare utilization trends among patients with opioid use disorder in U.S. Hospitals: an analysis of length of stay, total charges, and costs, 2005-2020.BMC health services research · 2025Article
- Methadone in the madness: a case series and review of methadone management in hospital settings.Pain management · 2025Review
- Article
- Medically assisted integrated rehabilitation program for people with opioid dependence: a quasi-experimental evaluation using multi-criteria decision analysis.BMC psychiatry · 2024Article
- Negative allosteric modulation of CB1 cannabinoid receptor signalling decreases intravenous morphine self-administration and relapse in mice.Addiction biology · 2024Article
- Childhood Traumas, Attachment Styles and Related Clinical Factors in Opioid Use Disorder.Noro psikiyatri arsivi · 2024Article
- Blockade of the Dopamine DNeuroscience bulletin · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies on high-risk opioid use have only focused on patients diagnosed with an opioid disorder. This study evaluates the impact of various high-risk prescription opioid use groups on healthcare costs and utilization.
methodsThis is a retrospective cohort study using QuintilesIMS health plan claims with independent variables from 2012 and outcomes from 2013. We included a population-based sample of 191,405 non-elderly adults with known sex, one or more opioid prescriptions, and continuous enrollment in 2012 and 2013. Three high-risk opioid use groups were identified in 2012 as (1) persons with 100+ morphine milligram equivalents per day for 90+ consecutive days (chronic users); (2) persons with 30+ days of concomitant opioid and benzodiazepine use (concomitant users); and (3) individuals diagnosed with an opioid use disorder. The length of time that a person had been characterized as a high-risk user was measured. Three healthcare costs (total, medical, and pharmacy costs) and four binary utilization indicators (the top 5% total cost users, the top 5% pharmacy cost users, any hospitalization, and any emergency department visit) derived from 2013 were outcomes. We applied a generalized linear model (GLM) with a log-link function and gamma distribution for costs while logistic regression was employed for utilization indicators. We also adopted propensity score weighting to control for the baseline differences between high-risk and non-high-risk opioid users.
resultsOf individuals with one or more opioid prescription, 1.45% were chronic users, 4.81% were concomitant users, and 0.94% were diagnosed as having an opioid use disorder. After adjustment and propensity score weighting, chronic users had statistically significant higher prospective total (40%), medical (3%), and pharmacy (172%) costs. The increases in total, medical, and pharmacy costs associated with concomitant users were 13%, 7%, and 41%, and 28%, 21% and 63% for users with a diagnosed opioid use disorder. Both total and pharmacy costs increased with the length of time characterized as high-risk users, with the increase being statistically significant. Only concomitant users were associated with a higher odds of hospitalization or emergency department use.
conclusionsIndividuals with high-risk prescription opioid use have significantly higher healthcare costs and utilization than their counterparts, especially those with chronic high-dose opioid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.